ClinicalTrials.gov
public full text
Public Domain
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
alzheimer-diseasebiomarkerdementiainflammationmental-disordersmild-cognitive-impairmentneurocognitive-disordersneurodegenerative-diseases
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease#844223
- Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease#1072862
- A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's#1007550
- Biomarker-based Trial of NPC-1 for Alzheimer's Pathology#897412
- ADDIA Proof-of-Performance Clinical Study#834477
Record · ID 1164530
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive